This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Candesartan
Accession Number
DB13919
Type
Small Molecule
Groups
Experimental
Description

Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is available as a prodrug in the form of Candesartan cilexetil.

Structure
Thumb
Synonyms
  • 2-ethoxy-1-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylic acid
External IDs
CV-11974
Categories
UNII
S8Q36MD2XX
CAS number
139481-59-7
Weight
Average: 440.454
Monoisotopic: 440.159688536
Chemical Formula
C24H20N6O3
InChI Key
HTQMVQVXFRQIKW-UHFFFAOYSA-N
InChI
InChI=1S/C24H20N6O3/c1-2-33-24-25-20-9-5-8-19(23(31)32)21(20)30(24)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)22-26-28-29-27-22/h3-13H,2,14H2,1H3,(H,31,32)(H,26,27,28,29)
IUPAC Name
2-ethoxy-1-{[2'-(1H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1H-1,3-benzodiazole-7-carboxylic acid
SMILES
CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
AType-1 angiotensin II receptor
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Candesartan.Experimental
AbirateroneThe metabolism of Candesartan can be decreased when combined with Abiraterone.Approved
AcebutololAcebutolol may increase the hypotensive activities of Candesartan.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Candesartan is combined with Aceclofenac.Approved, Investigational
AcemetacinThe therapeutic efficacy of Candesartan can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Candesartan is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Candesartan is combined with Adapalene.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Candesartan.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Candesartan is combined with Alclofenac.Approved, Withdrawn
AlfuzosinAlfuzosin may increase the hypotensive activities of Candesartan.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Candesartan.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Candesartan is combined with Alminoprofen.Experimental
AlprenololAlprenolol may increase the hypotensive activities of Candesartan.Approved, Withdrawn
AmbrisentanCandesartan may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineCandesartan may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideCandesartan may increase the hyperkalemic activities of Amiloride.Approved
AmiodaroneThe metabolism of Candesartan can be decreased when combined with Amiodarone.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Candesartan.Approved
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Candesartan.Approved, Investigational
AmphetamineAmphetamine may increase the hypotensive activities of Candesartan.Approved, Illicit
AndrographolideThe risk or severity of adverse effects can be increased when Candesartan is combined with Andrographolide.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Candesartan is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Candesartan is combined with Antipyrine.Approved
ApocyninThe risk or severity of adverse effects can be increased when Candesartan is combined with Apocynin.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Candesartan is combined with Apremilast.Approved, Investigational
AprepitantThe metabolism of Candesartan can be increased when combined with Aprepitant.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Candesartan.Approved
AvanafilAvanafil may increase the antihypertensive activities of Candesartan.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Candesartan is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Candesartan is combined with Azelastine.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Candesartan is combined with Balsalazide.Approved, Investigational
BarnidipineCandesartan may increase the antihypertensive activities of Barnidipine.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Candesartan is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Candesartan is combined with Bendazac.Experimental
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Candesartan.Approved
BenorilateThe risk or severity of adverse effects can be increased when Candesartan is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Candesartan is combined with Benoxaprofen.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Candesartan is combined with Benzydamine.Approved
BepridilBepridil may increase the hypotensive activities of Candesartan.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Candesartan.Approved
BethanidineBethanidine may increase the hypotensive activities of Candesartan.Approved
BevoniumThe risk or severity of adverse effects can be increased when Candesartan is combined with Bevonium.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Candesartan.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Candesartan.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Candesartan.Approved
BosentanBosentan may increase the hypotensive activities of Candesartan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Candesartan.Approved
BQ-123BQ-123 may increase the hypotensive activities of Candesartan.Investigational
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Candesartan.Approved
BretyliumBretylium may increase the hypotensive activities of Candesartan.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Candesartan.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Candesartan.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Candesartan is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Candesartan is combined with Bucillamine.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Candesartan is combined with Bufexamac.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Candesartan is combined with Bumadizone.Experimental
BupranololBupranolol may increase the hypotensive activities of Candesartan.Approved
CadralazineCadralazine may increase the hypotensive activities of Candesartan.Experimental
CafedrineCafedrine may increase the hypotensive activities of Candesartan.Investigational
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Candesartan.Approved
Candesartan cilexetilCandesartan cilexetil may increase the hypotensive activities of Candesartan.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candesartan is combined with Candoxatril.Experimental
CapecitabineThe metabolism of Candesartan can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Candesartan is combined with Captopril.Approved
CarbamazepineThe metabolism of Candesartan can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Candesartan is combined with Carbaspirin calcium.Experimental, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Candesartan is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Candesartan.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Candesartan.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Candesartan is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Candesartan is combined with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the hypotensive activities of Candesartan.Approved, Investigational
CeritinibThe serum concentration of Candesartan can be increased when it is combined with Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Candesartan is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Candesartan.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Candesartan.Approved
CholecalciferolThe metabolism of Candesartan can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Candesartan is combined with Choline magnesium trisalicylate.Approved
CicletanineCicletanine may increase the hypotensive activities of Candesartan.Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Candesartan is combined with Cilazapril.Approved
CiprofloxacinCandesartan may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
ClonidineClonidine may increase the hypotensive activities of Candesartan.Approved
ClonixinThe risk or severity of adverse effects can be increased when Candesartan is combined with Clonixin.Approved
CloranololCloranolol may increase the hypotensive activities of Candesartan.Experimental
ClotrimazoleThe metabolism of Candesartan can be decreased when combined with Clotrimazole.Approved, Vet Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Candesartan.Approved
CrisaboroleThe metabolism of Candesartan can be decreased when combined with Crisaborole.Approved, Investigational
CryptenamineCryptenamine may increase the hypotensive activities of Candesartan.Approved
CurcuminThe risk or severity of adverse effects can be increased when Candesartan is combined with Curcumin.Investigational
CyclopenthiazideCyclopenthiazide may increase the hypotensive activities of Candesartan.Experimental
CyclosporineCandesartan may increase the hyperkalemic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Candesartan.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Candesartan.Approved
DabrafenibThe serum concentration of Candesartan can be decreased when it is combined with Dabrafenib.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Candesartan.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Candesartan.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Candesartan is combined with Delapril.Experimental
DelavirdineThe metabolism of Candesartan can be decreased when combined with Delavirdine.Approved
DeserpidineCandesartan may increase the hypotensive activities of Deserpidine.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Candesartan.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Candesartan is combined with Diclofenac.Approved, Vet Approved
DiethylnorspermineDiethylnorspermine may increase the hypotensive activities of Candesartan.Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Candesartan is combined with Difenpiramide.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Candesartan is combined with Diflunisal.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Candesartan.Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Candesartan.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Candesartan.Approved
DosulepinThe metabolism of Candesartan can be decreased when combined with Dosulepin.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Candesartan.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Candesartan.Approved, Investigational
DrospirenoneCandesartan may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Candesartan is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Candesartan is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Candesartan is combined with E-6201.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Candesartan.Approved
EfavirenzThe metabolism of Candesartan can be decreased when combined with Efavirenz.Approved, Investigational
EfonidipineEfonidipine may increase the hypotensive activities of Candesartan.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Candesartan is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Candesartan is combined with Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Candesartan.Experimental
EpanololEpanolol may increase the hypotensive activities of Candesartan.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Candesartan is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Candesartan.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Candesartan.Approved
EprosartanEprosartan may increase the hypotensive activities of Candesartan.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Candesartan is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Candesartan is combined with Ethenzamide.Experimental
EtodolacThe risk or severity of adverse effects can be increased when Candesartan is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Candesartan is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Candesartan is combined with Etoricoxib.Approved, Investigational
EtravirineThe metabolism of Candesartan can be decreased when combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Candesartan is combined with Evening primrose oil.Approved, Investigational
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Candesartan.Approved
ExisulindThe risk or severity of adverse effects can be increased when Candesartan is combined with Exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Candesartan is combined with Felbinac.Experimental
FelodipineFelodipine may increase the hypotensive activities of Candesartan.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Candesartan is combined with Fenbufen.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Candesartan.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Candesartan is combined with Fenoprofen.Approved
FentiazacThe risk or severity of adverse effects can be increased when Candesartan is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Candesartan is combined with Feprazone.Experimental
Ferulic acidFerulic acid may increase the hypotensive activities of Candesartan.Experimental
FloctafenineThe risk or severity of adverse effects can be increased when Candesartan is combined with Floctafenine.Approved, Withdrawn
FloxuridineThe metabolism of Candesartan can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Candesartan can be decreased when combined with Fluconazole.Approved
FlunixinThe risk or severity of adverse effects can be increased when Candesartan is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Candesartan is combined with Flunoxaprofen.Experimental
FluorouracilThe metabolism of Candesartan can be decreased when combined with Fluorouracil.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Candesartan is combined with Flurbiprofen.Approved, Investigational
FluvastatinThe metabolism of Candesartan can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Candesartan can be decreased when combined with Fluvoxamine.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Candesartan is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Candesartan can be increased when combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Candesartan.Approved, Investigational, Vet Approved
GemfibrozilThe metabolism of Candesartan can be decreased when combined with Gemfibrozil.Approved
GuacetisalThe risk or severity of adverse effects can be increased when Candesartan is combined with Guacetisal.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Candesartan.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Candesartan.Approved
GuanazodineCandesartan may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Candesartan.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Candesartan.Approved, Investigational
GuanoclorCandesartan may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzCandesartan may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanCandesartan may increase the hypotensive activities of Guanoxan.Experimental
HarmalineHarmaline may increase the hypotensive activities of Candesartan.Experimental
HeparinHeparin may increase the hyperkalemic activities of Candesartan.Approved, Investigational
HexamethoniumHexamethonium may increase the hypotensive activities of Candesartan.Experimental
HigenamineThe risk or severity of adverse effects can be increased when Candesartan is combined with Higenamine.Investigational
HydralazineHydralazine may increase the hypotensive activities of Candesartan.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Candesartan.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Candesartan.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Candesartan is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Candesartan is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Candesartan is combined with Icatibant.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Candesartan is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Candesartan is combined with Imidazole salicylate.Experimental
IndapamideIndapamide may increase the hypotensive activities of Candesartan.Approved
IndenololIndenolol may increase the hypotensive activities of Candesartan.Withdrawn
IndinavirThe metabolism of Candesartan can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Candesartan is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Candesartan is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Candesartan is combined with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Candesartan.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Candesartan.Withdrawn
IrbesartanThe metabolism of Candesartan can be decreased when combined with Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Candesartan.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Candesartan is combined with Isoxicam.Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Candesartan.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Candesartan is combined with Kebuzone.Experimental
KetanserinKetanserin may increase the hypotensive activities of Candesartan.Investigational
KetoconazoleThe metabolism of Candesartan can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Candesartan is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Candesartan is combined with Ketorolac.Approved
LabetalolLabetalol may increase the hypotensive activities of Candesartan.Approved
LacidipineLacidipine may increase the hypotensive activities of Candesartan.Approved, Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Candesartan.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Candesartan.Approved
LeflunomideThe metabolism of Candesartan can be decreased when combined with Leflunomide.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Candesartan.Approved, Investigational
LinsidomineLinsidomine may increase the hypotensive activities of Candesartan.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Candesartan is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Candesartan is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Candesartan.Approved
LobeglitazoneThe metabolism of Candesartan can be decreased when combined with Lobeglitazone.Approved, Investigational
LofexidineLofexidine may increase the hypotensive activities of Candesartan.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Candesartan is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Candesartan is combined with Lornoxicam.Approved, Investigational
LosartanThe metabolism of Candesartan can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Candesartan can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Candesartan is combined with Loxoprofen.Approved, Investigational
LumacaftorThe serum concentration of Candesartan can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Candesartan is combined with Lumiracoxib.Approved, Investigational
MacitentanCandesartan may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Candesartan is combined with Magnesium salicylate.Approved
ManidipineThe metabolism of Candesartan can be decreased when combined with Manidipine.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Candesartan is combined with Masoprocol.Approved, Investigational
MecamylamineMecamylamine may increase the hypotensive activities of Candesartan.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Candesartan is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Candesartan is combined with Mefenamic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Candesartan is combined with Meloxicam.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Candesartan is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Candesartan is combined with Metamizole.Investigational, Withdrawn
MethoserpidineCandesartan may increase the hypotensive activities of Methoserpidine.Experimental
MethyldopaMethyldopa may increase the hypotensive activities of Candesartan.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Candesartan.Approved, Investigational
MetipranololMetipranolol may increase the hypotensive activities of Candesartan.Approved
MetolazoneMetolazone may increase the hypotensive activities of Candesartan.Approved
MetoprololMetoprolol may increase the hypotensive activities of Candesartan.Approved, Investigational
MetyrosineCandesartan may increase the hypotensive activities of Metyrosine.Approved
MibefradilMibefradil may increase the hypotensive activities of Candesartan.Investigational, Withdrawn
MidostaurinThe metabolism of Candesartan can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Candesartan can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Candesartan.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Candesartan.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Candesartan.Investigational
MizoribineThe risk or severity of adverse effects can be increased when Candesartan is combined with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Candesartan.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Candesartan is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Candesartan is combined with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Candesartan.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Candesartan.Approved, Investigational
MuzolimineMuzolimine may increase the hypotensive activities of Candesartan.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Candesartan is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Candesartan is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Candesartan is combined with Nabumetone.Approved
NadololNadolol may increase the hypotensive activities of Candesartan.Approved
NafamostatThe risk or severity of adverse effects can be increased when Candesartan is combined with Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Candesartan is combined with Naftifine.Approved
NaftopidilNaftopidil may increase the hypotensive activities of Candesartan.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Candesartan.Approved
NaproxenThe risk or severity of adverse effects can be increased when Candesartan is combined with Naproxen.Approved, Vet Approved
NebivololNebivolol may increase the hypotensive activities of Candesartan.Approved, Investigational
NepafenacThe risk or severity of adverse effects can be increased when Candesartan is combined with Nepafenac.Approved
NialamideNialamide may increase the hypotensive activities of Candesartan.Withdrawn
NicardipineThe metabolism of Candesartan can be decreased when combined with Nicardipine.Approved
NicorandilNicorandil may increase the hyperkalemic activities of Candesartan.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Candesartan is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Candesartan is combined with Niflumic Acid.Approved
NiguldipineNiguldipine may increase the hypotensive activities of Candesartan.Experimental
NilvadipineNilvadipine may increase the hypotensive activities of Candesartan.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Candesartan is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Candesartan.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Candesartan.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Candesartan.Approved, Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Candesartan is combined with Nitroaspirin.Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Candesartan.Approved
ObinutuzumabCandesartan may increase the hypotensive activities of Obinutuzumab.Approved
OlmesartanOlmesartan may increase the hypotensive activities of Candesartan.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Candesartan is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Candesartan is combined with Olsalazine.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Candesartan is combined with Omapatrilat.Investigational
OmeprazoleThe metabolism of Candesartan can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Candesartan is combined with Orgotein.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Candesartan is combined with Oxaprozin.Approved
OxprenololOxprenolol may increase the hypotensive activities of Candesartan.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Candesartan is combined with Oxyphenbutazone.Approved, Withdrawn
ParecoxibThe risk or severity of adverse effects can be increased when Candesartan is combined with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Candesartan.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Candesartan is combined with Parthenolide.Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Candesartan.Approved
PenbutololPenbutolol may increase the hypotensive activities of Candesartan.Approved, Investigational
PentoliniumPentolinium may increase the hypotensive activities of Candesartan.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Candesartan.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Candesartan is combined with Perindopril.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Candesartan.Approved
PhenobarbitalThe metabolism of Candesartan can be increased when combined with Phenobarbital.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Candesartan.Approved
PhentolaminePhentolamine may increase the hypotensive activities of Candesartan.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Candesartan is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe metabolism of Candesartan can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Candesartan is combined with Pimecrolimus.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Candesartan.Withdrawn
PindololPindolol may increase the hypotensive activities of Candesartan.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Candesartan is combined with Pirfenidone.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Candesartan.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Candesartan is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Candesartan is combined with Pirprofen.Experimental
Platelet Activating FactorPlatelet Activating Factor may increase the hypotensive activities of Candesartan.Experimental
PolythiazidePolythiazide may increase the hypotensive activities of Candesartan.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Candesartan is combined with Pranoprofen.Experimental, Investigational
PrazosinPrazosin may increase the hypotensive activities of Candesartan.Approved
PrimidoneThe metabolism of Candesartan can be increased when combined with Primidone.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Candesartan.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Candesartan is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Candesartan is combined with Propacetamol.Approved, Investigational
PropranololPropranolol may increase the hypotensive activities of Candesartan.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Candesartan is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Candesartan is combined with Proquazone.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Candesartan.Approved
PTC299The risk or severity of adverse effects can be increased when Candesartan is combined with PTC299.Investigational
PyrimethamineThe metabolism of Candesartan can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuinaprilThe risk or severity of adverse effects can be increased when Candesartan is combined with Quinapril.Approved, Investigational
QuinineThe metabolism of Candesartan can be decreased when combined with Quinine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Candesartan is combined with Ramipril.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Candesartan.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Candesartan.Approved
RemikirenRemikiren may increase the hypotensive activities of Candesartan.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Candesartan is combined with Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Candesartan.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Candesartan is combined with Resveratrol.Approved, Experimental, Investigational
RifampicinThe metabolism of Candesartan can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Candesartan can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Candesartan.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Candesartan.Investigational
RiociguatCandesartan may increase the hypotensive activities of Riociguat.Approved
RituximabCandesartan may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Candesartan is combined with Rofecoxib.Investigational, Withdrawn
RucaparibThe metabolism of Candesartan can be decreased when combined with Rucaparib.Approved, Investigational
SalicylamideThe risk or severity of adverse effects can be increased when Candesartan is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Candesartan is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Candesartan is combined with Salsalate.Approved
SaprisartanSaprisartan may increase the hypotensive activities of Candesartan.Experimental
SecobarbitalThe metabolism of Candesartan can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Candesartan.Approved, Investigational, Vet Approved
SelexipagSelexipag may increase the hypotensive activities of Candesartan.Approved
SemapimodThe risk or severity of adverse effects can be increased when Candesartan is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Candesartan is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Candesartan is combined with Serrapeptase.Investigational
SildenafilSildenafil may increase the antihypertensive activities of Candesartan.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Candesartan.Approved
SitaxentanCandesartan may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium phosphateCandesartan may increase the nephrotoxic activities of Sodium phosphate.Approved
SorafenibThe metabolism of Candesartan can be decreased when combined with Sorafenib.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Candesartan is combined with Spirapril.Approved
SRT501The risk or severity of adverse effects can be increased when Candesartan is combined with SRT501.Investigational
SulfadiazineThe metabolism of Candesartan can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Candesartan can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Candesartan is combined with Sulfasalazine.Approved
SulfisoxazoleThe metabolism of Candesartan can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Candesartan is combined with Sulindac.Approved
SuprofenThe risk or severity of adverse effects can be increased when Candesartan is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Candesartan is combined with Suxibuzone.Experimental
TadalafilTadalafil may increase the antihypertensive activities of Candesartan.Approved, Investigational
TalinololTalinolol may increase the hypotensive activities of Candesartan.Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Candesartan is combined with Tarenflurbil.Investigational
TelmisartanTelmisartan may increase the hypotensive activities of Candesartan.Approved, Investigational
TemocaprilThe risk or severity of adverse effects can be increased when Candesartan is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Candesartan is combined with Tenidap.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Candesartan is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Candesartan is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Candesartan is combined with Teriflunomide.Approved
TerlipressinTerlipressin may increase the hypotensive activities of Candesartan.Approved, Investigational
TetrahydropalmatineTetrahydropalmatine may increase the hypotensive activities of Candesartan.Investigational
TheodrenalineTheodrenaline may increase the hypotensive activities of Candesartan.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Candesartan is combined with Tiaprofenic acid.Approved
TiboloneTibolone may increase the hypotensive activities of Candesartan.Approved, Investigational
TicagrelorThe metabolism of Candesartan can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Candesartan can be decreased when combined with Ticlopidine.Approved
TicrynafenTicrynafen may increase the hypotensive activities of Candesartan.Withdrawn
TimololTimolol may increase the hypotensive activities of Candesartan.Approved
TinoridineThe risk or severity of adverse effects can be increased when Candesartan is combined with Tinoridine.Investigational
TolazolineTolazoline may increase the hypotensive activities of Candesartan.Approved, Vet Approved
TolbutamideThe metabolism of Candesartan can be decreased when combined with Tolbutamide.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Candesartan is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Candesartan is combined with Tolmetin.Approved
TolonidineCandesartan may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Candesartan.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Candesartan.Approved
TopiroxostatThe metabolism of Candesartan can be decreased when combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Candesartan.Approved, Investigational
TorasemideTorasemide may increase the hypotensive activities of Candesartan.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Candesartan is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Candesartan is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Candesartan.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Candesartan.Approved
TravoprostTravoprost may increase the hypotensive activities of Candesartan.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Candesartan.Approved, Investigational
TriamtereneCandesartan may increase the hyperkalemic activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Candesartan is combined with Tribenoside.Experimental
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Candesartan.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Candesartan.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Candesartan.Approved, Investigational
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Candesartan.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Candesartan is combined with Triptolide.Investigational
UdenafilUdenafil may increase the antihypertensive activities of Candesartan.Approved, Investigational
UnoprostoneUnoprostone may increase the hypotensive activities of Candesartan.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Candesartan.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Candesartan is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe metabolism of Candesartan can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Candesartan can be decreased when combined with Valsartan.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Candesartan.Approved
VincamineVincamine may increase the hypotensive activities of Candesartan.Experimental
VincristineThe excretion of Vincristine can be decreased when combined with Candesartan.Approved, Investigational
VinpocetineVinpocetine may increase the hypotensive activities of Candesartan.Investigational
VoriconazoleThe metabolism of Candesartan can be decreased when combined with Voriconazole.Approved, Investigational
XipamideXipamide may increase the hypotensive activities of Candesartan.Experimental
XylometazolineXylometazoline may increase the hypotensive activities of Candesartan.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Candesartan.Approved, Vet Approved
ZafirlukastThe metabolism of Candesartan can be decreased when combined with Zafirlukast.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Candesartan is combined with Zaltoprofen.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Candesartan is combined with Zileuton.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Candesartan is combined with Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Candesartan is combined with Zomepirac.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB14934
KEGG Drug
D00522
PubChem Compound
2541
PubChem Substance
347829334
ChemSpider
2445
BindingDB
50240609
ChEBI
3347
ChEMBL
CHEMBL1016
PharmGKB
PA448765
Wikipedia
Candesartan
ATC Codes
C09CA06 — CandesartanC09DB07 — Candesartan and amlodipineC09DA06 — Candesartan and diuretics

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00745 mg/mLALOGPS
logP3.44ALOGPS
logP4.68ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)3.44ChemAxon
pKa (Strongest Basic)1.5ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area118.81 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity134.92 m3·mol-1ChemAxon
Polarizability45.52 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-000i-0000900000-09252e3705ec18f28191
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-0a4r-0319500000-3993447974e9c0f96e19
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-0bu0-0916000000-066da93a95b0b10a64f7
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-001i-0901000000-e42def94ea7acc3e984c
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-001i-0902000000-9d8d5d747fc07188bcd6
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0a4i-0009000000-3f09ac2e45a45cf51567
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0000900000-c0732b3f672bdb0c5cd9
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0a4i-0429000000-e6666ddaea6b2fec4796
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-053r-0925000000-b2853a4d3ef881471918
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-001i-0901000000-e8293134d3b6edc1cc44
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-001i-0900000000-aad7b334b76f7066ae1e
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-001i-0900000000-e9298a423fa741683f4d
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0000900000-4332e0602a564f2c4578
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0a4i-0329000000-5bab9c66bf500046dd03
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-053r-0934000000-07766836cd4310e3c144
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-001i-0911000000-b335b08ddf551145ef5c
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-001i-0900000000-7cd909aa2c285aa2e22b
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-001i-0900000000-bf38bb169df6697bd345
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0a4i-0009000000-dffef5ed5958e9c3aa46
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-053i-0829800000-75336f6b69959f06951d
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03dl-0060900000-c21ae83183c0c4c66d20
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03dr-0092200000-c93d18ca0f8aace375e7
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-06rl-0392000000-c3ccc11e70e6108541a5
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4l-0982000000-48b2e463d5df0f082d64
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4l-0941000000-960f676aef7b7f30eb65
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03k9-0090800000-8aaa172c9293c5ae972a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0090400000-d1a491f53255bc054efe
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03dr-0192000000-7f13db6e80afed497be0
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-052f-0892000000-fbf84d949230e0f7cdcf
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-0931000000-f09988e63e0ff1ee7c41
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00kf-0920000000-4eb700bf722035bbc5e6
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0ftf-0910000000-8a887e64aa26b17819f1
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0090400000-8977fe66c12ae5daf842
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03dr-0192000000-e19af79847787e125480
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-052f-0892000000-aadfb13bbceced2abed1
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-0931000000-30b595e099863925404a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-0910000000-b0e858bc66d29221b761
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0ftf-0910000000-0468a1554ab3d27acb6e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03k9-0090800000-498c7dbf4edcf24086ae
MS/MS Spectrum - , positiveLC-MS/MSsplash10-08mi-1693300000-e31b853c08a2b3f6b0ab
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-0692200000-2d47b15f47b41bdbebed

Taxonomy

Description
This compound belongs to the class of organic compounds known as biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Biphenyls and derivatives
Direct Parent
Biphenyls and derivatives
Alternative Parents
Phenyltetrazoles and derivatives / Benzimidazoles / Alkyl aryl ethers / N-substituted imidazoles / Vinylogous amides / Heteroaromatic compounds / Monocarboxylic acids and derivatives / Carboxylic acids / Azacyclic compounds / Organopnictogen compounds
show 3 more
Substituents
Biphenyl / Phenyltetrazole / Benzimidazole / Alkyl aryl ether / N-substituted imidazole / Azole / Imidazole / Heteroaromatic compound / Vinylogous amide / Tetrazole
show 14 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
biphenylyltetrazole, benzimidazolecarboxylic acid (CHEBI:3347)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name
AGTR1
Uniprot ID
P30556
Uniprot Name
Type-1 angiotensin II receptor
Molecular Weight
41060.53 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Cervenka L, Navar LG: Renal responses of the nonclipped kidney of two-kidney/one-clip Goldblatt hypertensive rats to type 1 angiotensin II receptor blockade with candesartan. J Am Soc Nephrol. 1999 Jan;10 Suppl 11:S197-201. [PubMed:9892163]
  3. Malmqvist K, Kahan T, Dahl M: Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide. Am J Hypertens. 2000 May;13(5 Pt 1):504-11. [PubMed:10826401]
  4. Wada T, Inada Y, Ojima M, Sanada T, Shibouta Y, Nishikawa K: Comparison of the antihypertensive effects of the new angiotensin II (AT1) receptor antagonist candesartan cilexetil (TCV-116) and the angiotensin converting enzyme inhibitor enalapril in rats. Hypertens Res. 1996 Jun;19(2):75-81. [PubMed:10968199]
  5. Engelhorn T, Doerfler A, Heusch G, Schulz R: Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats. Neurosci Lett. 2006 Oct 2;406(1-2):92-6. Epub 2006 Aug 9. [PubMed:16901636]
  6. Caballero-George C, Vanderheyden PM, Solis PN, Gupta MP, Pieters L, Vauquelin G, Vlietinck A: In vitro effect of sanguinarine alkaloid on binding of [3H]candesartan to the human angiotensin AT1 receptor. Eur J Pharmacol. 2003 Jan 5;458(3):257-62. [PubMed:12504781]
  7. McInnes GT, O'Kane KP, Istad H, Keinanen-Kiukaanniemi S, Van Mierlo HF: Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients. J Hum Hypertens. 2000 Apr;14(4):263-9. [PubMed:10805052]
  8. Vauquelin G, Fierens F, Van Liefde I: Long-lasting angiotensin type 1 receptor binding and protection by candesartan: comparison with other biphenyl-tetrazole sartans. J Hypertens Suppl. 2006 Mar;24(1):S23-30. [PubMed:16601569]
  9. Mendis B, Page SR: Candesartan: widening indications for this angiotensin II receptor blocker? Expert Opin Pharmacother. 2009 Aug;10(12):1995-2007. doi: 10.1517/14656560903092197. [PubMed:19563275]
  10. Meredith PA: Candesartan cilexetil--a review of effects on cardiovascular complications in hypertension and chronic heart failure. Curr Med Res Opin. 2007 Jul;23(7):1693-705. [PubMed:17588300]
  11. Baguet JP, Barone-Rochette G, Neuder Y: Candesartan cilexetil in the treatment of chronic heart failure. Vasc Health Risk Manag. 2009;5(1):257-64. Epub 2009 Apr 8. [PubMed:19436650]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. [PubMed:15601807]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. McClellan KJ, Goa KL: Candesartan cilexetil. A review of its use in essential hypertension. Drugs. 1998 Nov;56(5):847-69. [PubMed:9829158]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative reg...
Gene Name
UGT1A3
Uniprot ID
P35503
Uniprot Name
UDP-glucuronosyltransferase 1-3
Molecular Weight
60337.835 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500. [PubMed:11895100]

Drug created on October 22, 2017 11:19 / Updated on November 09, 2017 05:20